TMDX TransMedics Group, Inc.
HealthcareAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
19.35
PEG
0.04
P/B
4.80
P/S
3.75
EV/EBITDA
19.94
DCF Value
$-1,150.76
FCF Yield
6.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
59.1%
Operating Margin
14.9%
Net Margin
27.0%
ROE
41.9%
ROA
12.0%
ROIC
6.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $173.9M | $7.3M | $— |
| Q4 null | $160.8M | $105.4M | $— |
| FY null | $605.5M | $190.3M | $— |
| Q3 null | $143.8M | $24.3M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$124.33
Target (Median)
$129.50
Target Range
$85.00 - $142.00
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
2.06
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.